Literature DB >> 2893415

Antagonism by cholinomimetic drugs of the turning induced by intrastriatal pirenzepine in mice.

P Worms1, K Biziere.   

Abstract

In order to investigate the behavioural effect of selective blockade of M1 muscarinic receptors in the forebrain, and to characterize a new model for the evaluation of muscarinic agonistic activity, the effect of intrastriatally injected pirenzepine was studied in mice. The direct injection of pirenzepine (0.01-1 microgram/mouse) into the right striatum of conscious mice resulted in contralateral turning behaviour. When injected intraperitoneally (IP) 15 min before pirenzepine (1 microgram), the muscarinic receptor agonists arecoline and pilocarpine (0.3-3 mg/kg), oxotremorine (0.003-0.03 mg/kg) and RS 86 (0.03-1 mg/kg) antagonized pirenzepine-induced turning, as did the choline-esterase inhibitor physostigmine (0.01-0.1 mg/kg) and the nootropic drug aniracetam (10-30 mg/kg). Haloperidol (0.03-0.3 mg/kg IP) weakly, but significantly, decreased the effect of pirenzepine, whereas (+/-) sulpiride (3-100 mg/kg) failed to affect it. Finally, (+/-)-amphetamine (0.1-3 mg/kg IP), citalopram (1-30 mg/kg IP) and muscimol (0.03-0.3 mg/kg IP) failed to modify pirenzepine-induced turning when administered prior to intrastriatal pirenzepine. These results suggest an involvement of M1 muscarinic receptors in rotational behaviour, and indicate that pirenzepine-induced turning may represent a new model for studying the central activity of cholinomimetic drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2893415     DOI: 10.1007/bf00207240

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  The interaction of neuroleptic and muscarinic agents with central dopaminergic systems.

Authors:  P H Kelly; R J Miller
Journal:  Br J Pharmacol       Date:  1975-05       Impact factor: 8.739

2.  Some biochemical and behavioural correlates of a possible animal model of human hyperkinetic syndromes.

Authors:  G M McKenzie; R J Gordon; K Viik
Journal:  Brain Res       Date:  1972-12-12       Impact factor: 3.252

3.  Methylphenidate antagonism of haloperidol, interaction with cholinergic and anticholinergic drugs.

Authors:  B Fjalland; I Moller Nielsen
Journal:  Psychopharmacologia       Date:  1974-01-11

4.  Cholinergic modulation of stimulant-induced behavior.

Authors:  L P Gonzalez; E H Ellinwood
Journal:  Pharmacol Biochem Behav       Date:  1984-03       Impact factor: 3.533

5.  Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain.

Authors:  M Raiteri; R Leardi; M Marchi
Journal:  J Pharmacol Exp Ther       Date:  1984-01       Impact factor: 4.030

6.  The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro-[4,5]-decan-1,3-dion hydrobromide). A potent, specific muscarinic acetylcholine receptor agonist.

Authors:  J M Palacios; G Bolliger; A Closse; A Enz; G Gmelin; J Malanowski
Journal:  Eur J Pharmacol       Date:  1986-06-05       Impact factor: 4.432

7.  Muscarinic receptors on dopamine terminals in the cat caudate nucleus: neuromodulation of [3H]dopamine release in vitro by endogenous acetylcholine.

Authors:  J Lehmann; S Z Langer
Journal:  Brain Res       Date:  1982-09-23       Impact factor: 3.252

8.  Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine.

Authors:  J K Wamsley; D R Gehlert; W R Roeske; H I Yamamura
Journal:  Life Sci       Date:  1984-04-02       Impact factor: 5.037

9.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

Review 10.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

View more
  4 in total

1.  Systemic injection of pirenzepine induces a deficit in passive avoidance learning in rats.

Authors:  P Worms; C Gueudet; A Pério; P Soubrié
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Cholinomimetic activities of minaprine.

Authors:  P Worms; J P Kan; R Steinberg; J P Terranova; A Perio; K Biziere
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

3.  SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome.

Authors:  J P Kan; R Steinberg; F Oury-Donat; J C Michaud; O Thurneyssen; J P Terranova; C Gueudet; J Souilhac; R Brodin; R Boigegrain
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 4.  Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.

Authors:  C R Lee; P Benfield
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.